Sorafenib Maintenance Therapy for Patients With AML After Allogeneic Stem Cell Transplant

NCT01398501 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

22

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: Sorafenib

Sponsor

Massachusetts General Hospital

Collaborators

[object Object]